We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Measurement of Urinary Ethyl Glucuronide Recommended for Monitoring Alcohol Abuse Following Liver Transplant

By LabMedica International staff writers
Posted on 20 May 2014
Print article
As damage to the liver from consumption of ethanol is one of the most common reasons for liver transplantation, it is of vital importance to the clinician to be aware if the recipient of a transplant continues to drink alcoholic beverages.

To determine how alcohol consumption should best be monitored, investigators at the University of Padua (Italy) evaluated the efficacy of several direct tests to detect alcohol in a target group of 121 liver transplant candidates and recipients. The investigators evaluated urinary ethyl glucuronide (uEtG), the Alcohol Use Disorders Identification Test for alcohol consumption (AUDIT-c), serum ethanol (sETOH), urinary ethanol (uETOH), and carbohydrate-deficient transferrin (CDT).

The Alcohol Use Disorders Identification Test (AUDIT-C) is an alcohol screen questionnaire that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence).

Ethyl glucuronide (EtG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol, such as by drinking alcoholic beverages. It is used as a biomarker to test for ethanol use and to monitor or document alcohol abstinence in situations where drinking is prohibited. In addition to its use to monitor abstinence and detect drinking EtG also has potential for monitoring amount of alcohol use over time because it can be detected in hair and nails. A disadvantage of the test is that because EtG can be detected in samples at very low levels, it can also be positive after exposure to alcohol from nonbeverage sources, or incidental exposure, which can lead to innocent positives.

Serum and urine ethanol testing are linked to the fact that peak urine alcohol levels are reached 45 to 60 minutes after alcohol ingestion. At this time, urine alcohol levels are typically about 1.3 times greater than the corresponding blood alcohol concentration. This ratio is only valid during the elimination phase, which occurs after the blood alcohol level has peaked and is decreasing. Alcohol may be detected in the urine for one to two hours longer than it is detected in blood. The presence of alcohol in the urine indicates recent prior use, but may not correlate with the degree of intoxication observed at the time of testing.

Chronic alcoholism causes a transient change in the glycosylation pattern of the blood protein transferrin where the relative amounts of disialo- and asialotransferrin (carbohydrate deficient transferring or CDT) are increased over the amount of normally glycosylated tetrasialotransferrin. This recognition led to the use of CDT in serum as marker for chronic alcohol abuse. CDT typically normalizes within several weeks of abstinence of alcohol use. There are other causes of abnormal CDT levels, which include congenital disorders of glycosylation and other genetic and non-genetic causes of acute or chronic liver disease.

For the current study alcohol consumption was defined by a positive AUDIT-c or when it was confirmed by patient history in response to abnormal results. Alcohol consumption was found in 30.6% of patients. uEtG was found to be the strongest marker of alcohol consumption and showed a more accurate prediction rate of alcohol consumption when compared to CDT. The combination of uEtG with AUDIT-c showed a higher accuracy in detecting alcohol consumption when compared to the combination of CDT and AUDIT-c. Furthermore, uEtG was the most useful marker for detecting alcohol consumption in patients with a negative AUDIT-c.

"Assessing alcohol consumption is crucial in the selection of liver transplant candidates," said senior author Dr. Paolo Angeli, associate professor of medicine at the University of Padua. "Equally important is the ability to detect alcohol use in liver transplant recipients so early intervention for alcohol relapse can take place. It is vital that patients abstain from damaging drinking behavior following liver transplant to avoid graft loss or even death. When used together, uEtG and AUDIT-c provide an important tool in the management of transplant patients at risk for alcohol relapse."

The study was published in the May 2014 online edition of the journal Liver Transplantation.

Related Links:

University of Padua


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.